110 results
Page 4 of 6
6-K
EX-99
anhfua
9 Feb 15
2015 Annual General Meeting of Shareholders
12:00am
6-K
EX-99
wz7c78m15j1 p34kxb
5 Nov 14
BioLineRx Announces Successful Final Results of
12:00am
6-K
EX-99
v94mxy3jhmki7 2re91
21 Aug 14
BioLineRx Receives Notice of Allowance for US Patent on BL-7010
12:00am
6-K
EX-99
qfdxipfqo
16 Jul 14
BioLineRx Announces Results from
12:00am
6-K
EX-1
cgj1262 jcu6ir5
23 Jun 14
Current report (foreign)
12:00am
424B2
y9jxn8rorkxrm7xg4o6
13 Jun 14
Prospectus for primary offering
12:00am
6-K
EX-1
9xe2v
11 Jun 14
Current report (foreign)
12:00am
6-K
EX-1.1
adpn6yzb57vaiei
30 May 14
Current report (foreign)
12:00am
F-3
jmblc8n30338
30 May 14
Shelf registration (foreign)
12:00am
6-K
EX-99
9ibpyb1sz
10 Mar 14
BioLineRx Completes Dose Escalation Stage of Phase 1/2 Study
12:00am
6-K
EX-1.1
nivhxe4dog2b9o
7 Mar 14
BioLineRx Closes $24.1 Million Underwritten Public Offering
12:00am
424B5
ian20bx 6ui7fvsm98
4 Mar 14
Prospectus supplement for primary offering
12:00am
424B5
0jvl980cj0yf
3 Mar 14
Prospectus supplement for primary offering
12:00am
6-K
EX-99
n4onw7bo22klog
18 Dec 13
Current report (foreign)
12:00am
6-K
EX-99
7hporwj3
4 Nov 13
BioLineRx Receives Regulatory Approval to Commence
12:00am
6-K
EX-99
9hm u8iwfn2n
24 Sep 13
BioLineRx Announces Regulatory Submission for Phase
12:00am
6-K
EX-99
o9if1 25ak1i
19 Aug 13
BioLineRx Appoints B. J. Bormann to
12:00am
424B3
xkoulb
8 Aug 13
Prospectus supplement
12:00am